## CORRECTION



# Correction: Exploring the effect of Yinzhihuang granules on alcoholic liver disease based on pharmacodynamics, network pharmacology and molecular docking

Yingying Tan<sup>1†</sup>, Fanqin Zhang<sup>1†</sup>, Xiaotian Fan<sup>1</sup>, Shan Lu<sup>1</sup>, Yingying Liu<sup>1</sup>, Zhishan Wu<sup>1</sup>, Zhihong Huang<sup>1</sup>, Chao Wu<sup>1</sup>, Guoliang Cheng<sup>2</sup>, Bing Li<sup>2</sup>, Jiaqi Huang<sup>1</sup>, Antony Stalin<sup>3\*</sup>, Wei Zhou<sup>4\*</sup> and Jiarui Wu<sup>1\*</sup>

### Correction: Chinese Medicine (2023) 18:52 https://doi.org/10.1186/s13020-023-00759-z

Following publication of the original article [1], the authors reported an error in the Experimental animal model and drug interventions section.

The original content is as follows:

After 1 week of adaptive feeding, mice were randomly divided into 6 groups (n=6), namely control group (C), model group (M), **3.5 mg/kg** of positive group (P), 3.69 g/ kg of YZHG low dose group (YL), 7.38 g/kg of YZHG

<sup>†</sup>Yingying Tan and Fanqin Zhang contributed equally to this work.

The online version of the original article can be found at https://doi.org/10. 1186/s13020-023-00759-z.

\*Correspondence: Antony Stalin a.staanlin@gmail.com Wei Zhou weizhou19940530@163.com Jiarui Wu exogamy@163.com <sup>1</sup> Department of Clinical Chinese Pharmacy, School of Chinese Materia Medica, Beijing University of Chinese Medicine, Beijing, China <sup>2</sup> State Key Laboratory of Generic Manufacture Technology of Chinese Traditional Medicine, Linyi, China <sup>3</sup> Institute of Fundamental and Frontier Sciences, University of Electronic

Science and Technology of China, Chengdu, China

medium dose group (YM) and 14.76 g/kg of YZHG high dose group (YH). The doses of the positive drug (silibinin capsule) and YZHG were converted into corresponding doses based on the body surface area of humans and animals.

The revised content is as follows:

After 1 week of adaptive feeding, mice were randomly divided into 6 groups (n=6), namely control group (C), model group (M), **43.05 mg/kg** of positive group (P), 3.69 g/kg of YZHG low dose group (YL), 7.38 g/kg of YZHG medium dose group (YM) and 14.76 g/kg of YZHG high dose group (YH). The doses of the positive drug (silibinin capsule) and YZHG were converted into corresponding doses based on the body surface area of humans and animals.

The original article [1] has been corrected.

Published online: 10 July 2023

#### Reference

 Tan Y, Zhang F, Fan X, Lu S, Liu Y, Wu Z, Huang Z, Wu C, Cheng G, Li B, Huang J, Stalin A, Zhou W, Wu J. Exploring the effect of Yinzhihuang granules on alcoholic liver disease based on pharmacodynamics, network



© The Author(s) 2023. **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/lublicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

<sup>&</sup>lt;sup>4</sup> Department of Pharmacy, Friendship Hospital, Beijing 100029, China

pharmacology and molecular docking. Chin Med. 2023;18:52. https://doi. org/10.1186/s13020-023-00759-z.

#### **Publisher's Note**

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

#### Ready to submit your research? Choose BMC and benefit from:

- fast, convenient online submission
- thorough peer review by experienced researchers in your field
- rapid publication on acceptance
- support for research data, including large and complex data types
- gold Open Access which fosters wider collaboration and increased citations
- maximum visibility for your research: over 100M website views per year

#### At BMC, research is always in progress.

Learn more biomedcentral.com/submissions

